Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients

Sexually Transmitted Diseases

Volumn 30, Issue 7, 2003, Pages 575-580

  Castle, Philip E ^a   Escoffery, Carlos ^b   Schachter, Julius ^c   Rattray, Carole ^b   Schiffman, Mark ^a   Moncada, Jeanne ^c   Sugai, Karlyn ^c   Brown, Claudette ^b   Cranston, Beverly ^b   Hanchard, Barrie ^b   Palefsky, Joel M ^c   Burk, Robert D ^d   Hutchinson, Martha L ^e   Strickler, Howard D ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ANTIBODY DETECTION; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COLPOSCOPY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC CANCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LIGASE CHAIN REACTION; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; SEROLOGY; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WESTERN BLOTTING;

EID: 0037998940     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200307000-00009     Document Type: Article

References (27)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study On Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
3. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85:958-964.
4. Smith JS, Munoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002; 185:324-331.
5. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285:47-51.
6. Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94:1604-1613.
7. Murai K, Tachibana N, Shioiri S, et al. Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers. J Acquir Immun Defic Syndr 1990; 3:1006-1009.
8. Miyazaki K, Yamaguchi K, Tohya T, Ohba T, Takatsuki K, Okamura H. Human T-cell leukemia virus type I infection as an oncogenic and prognostic risk factor in cervical and vaginal carcinoma. Obstet Gynecol 1991; 77:107-110.
9. Strickler HD, Rattray C, Escoffery C, et al. Human T-cell lymphotropic virus type I and severe neoplasia of the cervix in Jamaica. Int J Cancer 1995; 61:23-26.
10. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92:464-474.
11. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91:252-258.
12. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285:1500-1505.
13. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997; 35:1304-1310.
14. Briggs NC, Battjes RJ, Cantor KP, et al. Seroprevalence of human T cell lymphotropic virus type II infection, with or without human immunodeficiency virus type 1 coinfection, among US intravenous drug users. J Infect Dis 1995; 172:51-58.
15. Wiktor SZ, Alexander SS, Shaw GM, et al. Distinguishing between HTLV-I and HTLV-II by western blot. Lancet 1990; 335:1533.
16. Schachter J, Stamm WE, Quinn TC, Andrews WW, Burczak JD, Lee HH. Ligase chain reaction to detect Chlamydia trachomatis infection of the cervix. J Clin Microbiol 1994; 32:2540-2543.
17. Wang SP, Grayston JT, Alexander ER, Holmes KK. Simplified microimmunofluorescence test with trachoma-lymphogranuloma venereum (Chlamydia trachomatis) antigens for use as a screening test for antibody. J Clin Microbiol 1975; 1:250-255.
18. Jones HM, Schachter J, Stephens RS. Evaluation of the humoral immune response in trachoma to Chlamydia trachomatis major outer membrane proteins by sequence-defined immunoassay. J Infect Dis 1992; 166:915-919.
19. Ashley RL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect 2001; 77:232-237.
20. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001; 183:1554-1564.
21. Hanchard B, Blake G, Wolff C, et al. Age-specific incidence of cancer in Kingston and St Andrew, Jamaica, 1993-1997. West Indian Med J 2001;50:123-129.
22. Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet 1999; 353:1951-1958.
23. Schmauz R, Okong P, de Villiers EM, et al. Multiple infections in cases of cervical cancer from a high-incidence area in tropical Africa. Int J Cancer 1989; 43:805-809.
24. Koskela P, Anttila T, Bjorge T, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000; 85:35-39.
25. Gravitt PE, Castle PE. Chlamydia trachomatis and cervical squamous cell carcinoma. JAMA 2001; 285:1703-1704.
26. Strickler HD, Kirk GD, Figueroa JP, et al. HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int J Cancer 1999; 80:339-344.
27. Murphy EL, Wu Y, Ownby HE, et al. Delayed hypersensitivity skin testing to mumps and Candida albicans antigens is normal in middle-aged HTLV-I- and -II-infected U.S. cohorts. AIDS Res Hum Retroviruses 2001; 17:1273-1277.